NZ552335A - Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent - Google Patents

Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent

Info

Publication number
NZ552335A
NZ552335A NZ552335A NZ55233502A NZ552335A NZ 552335 A NZ552335 A NZ 552335A NZ 552335 A NZ552335 A NZ 552335A NZ 55233502 A NZ55233502 A NZ 55233502A NZ 552335 A NZ552335 A NZ 552335A
Authority
NZ
New Zealand
Prior art keywords
fluoro
methyl
chloro
inhibitor
hydrogen
Prior art date
Application number
NZ552335A
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ552335A publication Critical patent/NZ552335A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
NZ552335A 2001-10-25 2002-10-24 Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent NZ552335A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34473501P 2001-10-25 2001-10-25
US34473401P 2001-10-25 2001-10-25
US33603301P 2001-11-15 2001-11-15

Publications (1)

Publication Number Publication Date
NZ552335A true NZ552335A (en) 2008-11-28

Family

ID=27407094

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ532418A NZ532418A (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent
NZ552335A NZ552335A (en) 2001-10-25 2002-10-24 Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ532418A NZ532418A (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent

Country Status (23)

Country Link
US (2) US20050043409A1 (es)
EP (1) EP1441714B1 (es)
JP (1) JP2005506366A (es)
KR (1) KR100954625B1 (es)
CN (1) CN100506224C (es)
AT (1) ATE381930T1 (es)
AU (2) AU2006252156A1 (es)
BR (1) BR0213486A (es)
CA (1) CA2464309C (es)
CY (1) CY1108045T1 (es)
DE (1) DE60224299T2 (es)
DK (1) DK1441714T3 (es)
ES (1) ES2295428T3 (es)
HK (1) HK1068261A1 (es)
HU (1) HUP0600235A3 (es)
IL (1) IL161462A0 (es)
MX (1) MXPA04003878A (es)
NZ (2) NZ532418A (es)
PL (1) PL369305A1 (es)
PT (1) PT1441714E (es)
RU (1) RU2333754C2 (es)
SI (1) SI1441714T1 (es)
WO (1) WO2003035047A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
WO2005027972A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
JP2007505939A (ja) * 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と他の治療剤の組み合わせ
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1479385E (pt) * 1996-10-15 2008-09-02 Searle Llc Utilização de inibidores de ciclo-oxigenase 2 no tratamento e na prevenção de neoplasias
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
IL143901A0 (en) * 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
KR20020018201A (ko) * 1999-08-12 2002-03-07 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물
JP2003517475A (ja) * 1999-12-03 2003-05-27 ファイザー・プロダクツ・インク 抗炎症／鎮痛薬としてのヘテロシクロ−アルキルスルホニルピラゾール誘導体
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT OR PREVENTION OF PROSTATE CANCER USING A SELECTIVE COX-2 INHIBITOR MEDICINE
WO2001062252A1 (en) * 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
AU2001232175B2 (en) * 2000-03-03 2005-07-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
NZ532418A (en) 2007-02-23
PT1441714E (pt) 2008-03-10
KR20040048992A (ko) 2004-06-10
DK1441714T3 (da) 2008-03-31
HUP0600235A2 (en) 2007-02-28
SI1441714T1 (sl) 2008-06-30
HUP0600235A3 (en) 2008-04-28
AU2010200433A1 (en) 2010-02-25
DE60224299D1 (de) 2008-02-07
RU2333754C2 (ru) 2008-09-20
EP1441714B1 (en) 2007-12-26
ATE381930T1 (de) 2008-01-15
PL369305A1 (en) 2005-04-18
EP1441714A2 (en) 2004-08-04
ES2295428T3 (es) 2008-04-16
JP2005506366A (ja) 2005-03-03
DE60224299T2 (de) 2008-12-11
AU2006252156A1 (en) 2007-01-18
BR0213486A (pt) 2005-05-10
CN100506224C (zh) 2009-07-01
WO2003035047A3 (en) 2003-10-23
KR100954625B1 (ko) 2010-04-27
MXPA04003878A (es) 2004-07-08
CN1575168A (zh) 2005-02-02
RU2004116069A (ru) 2005-06-10
US20050043409A1 (en) 2005-02-24
WO2003035047A2 (en) 2003-05-01
CA2464309C (en) 2012-01-03
HK1068261A1 (en) 2005-04-29
US20110046190A1 (en) 2011-02-24
CA2464309A1 (en) 2003-05-01
CY1108045T1 (el) 2013-09-04
IL161462A0 (en) 2004-09-27

Similar Documents

Publication Publication Date Title
US20110046190A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
US20060270665A1 (en) Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
RU2660354C2 (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN106456635A (zh) Mdm2抑制剂的间歇给药
MX2008016125A (es) Compuestos organicos.
US7723339B2 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
RU2469721C2 (ru) Комбинация, включающая комплексон железа и противоопухолевый агент, и ее применение
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
ZA200402939B (en) Combinations comprising a selective cyclooxygenase-2 inhibitor.
AU2002351784A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
MX2012015040A (es) Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal.
TW200950789A (en) Antitumor agent, kit and method of treating cancer
TWI343258B (en) Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative
CN117377492A (zh) 包含蛋白激酶抑制剂的药物组合物及其医药用途
NZ615005A (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
NZ615005B2 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed